Tech Company Financing Transactions

Inversago Pharma Funding Round

On 10/17/2022, Inversago Pharma raised $69 million in Series C financing from New Enterprise Associates, adMare BioInnovations and Amgen Ventures.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1 Place Ville Marie 1670
Montreal QC, H3B 2B6
Canada

Phone

Undisclosed

Website

www.inversago.com

Email Address

[email protected]

Overview

A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

François Ravenelle

        

Chief Financial Officer

Micheline Beauvais

        

Chief Medical Officer

Christine McCarthy

        

VP - R & D

Caroline Fradette

        

Browse more venture capital transactions:

Prev: 10/17/2022: Mobility Work venture capital transaction
Next: 10/17/2022: Surge Therapeutics venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary